To include your compound in the COVID-19 Resource Center, submit it here.

Pact’s $75M series C gives Vida’s Kite alumni long-sought stab at personalized cell therapy

By leading Pact Pharma Inc.’s $75 million series C round, the ex-Kite partners at Vida Ventures finally have a chance to advance neoantigen-specific T cells for solid tumors, an area of keen interest they weren’t able

Read the full 360 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE